Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Registration Number
- NCT04437160
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Brief Summary
This study will evaluate the efficacy and safety of antharcycline-based adjuvant chemotherapy compared with observation in triple negative breast cancer (TNBC) patients with residual invasive disease after platinum and taxanes based neoadjuvant chemotherapy.
- Detailed Description
This study is a multi-center, randomized, phase II study. TNBC patients with residual invasive disease (invasive breast tumor size≥1cm and/or positive axillary lymph nodes) after platinum and taxanes based neoadjuvant chemotherapy are enrolled (n = 286). Patients are assigned to the chemotherapy group or the observation group at a 1:1 ratio randomly 4-6 weeks after surgery. Patients in the chemotherapy group are given anthracycline combined with cyclophosphamide regimen for 4 cycles. At the same time, the blood and tissue samples are collected for relevant tests. Follow up every 3-6 months and record recurrences and deaths.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 286
- Patients with histologically confirmed invasive adenocarcinoma of the breast.
- Triple negative breast cancer: hormone receptor negative (ER < 10% and PgR < 10%) and HER2 negative (IHC 0/1+ or ISH non-amplified), as defined by the local pathology laboratory.
- Clinical stage at presentation: T1-4, N0-3, M0, with indications for neoadjuvant chemotherapy.
- Patient must have received platinum and taxanes neoadjuvant chemotherapy for at least 4 cycles and no tumor progression occurred.
- Patients should have undergone adequate tumor excision in the breast and lymph nodes after neoadjuvant chemotherapy.
- Residual invasive disease must be ≥1cm in the breast, and/or have positive axillary lymph nodes observed on pathologic exam after neoadjuvant chemotherapy.
- ECOG Performance Status: 0-1.
- Patients without severe heart, lung, liver and kidney disease.
- Adequate hematologic and end-organ function.
- No more than 6 weeks may elapse between definitive breast surgery and randomization.
- Previous neoadjuvant chemotherapy with anthracycline or other drugs (except platinum and taxanes).
- Previous neoadjuvant chemotherapy with platinum or taxanes alone.
- Patients have received other adjuvant therapy.
- Comprehensive medical examinations have revealed distant metastases before randomization.
- Patients who are not suitable for anthracycline evaluated by investigators.
- Prior history of other malignancy (except carcinoma in situ).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Adjuvant chemotherapy Epirubicin or Pirarubicin Adjuvant chemotherapy for triple negative breast cancer with residual invasive disease (invasive breast tumor size≥1cm and/or positive axillary lymph nodes) after taxanes and platinum based neoadjuvant chemotherapy. Adjuvant chemotherapy regiments: Epirubicin 80-90mg/m2 IV or Pirarubicin 50mg/m2 IV + Cyclophosphamide 600mg/m2 IV, q21d\*4cycles. Adjuvant chemotherapy Cyclophosphamide Adjuvant chemotherapy for triple negative breast cancer with residual invasive disease (invasive breast tumor size≥1cm and/or positive axillary lymph nodes) after taxanes and platinum based neoadjuvant chemotherapy. Adjuvant chemotherapy regiments: Epirubicin 80-90mg/m2 IV or Pirarubicin 50mg/m2 IV + Cyclophosphamide 600mg/m2 IV, q21d\*4cycles.
- Primary Outcome Measures
Name Time Method RFS median 5 years RFS defined as the time from randomization to the first recurrence event or death through the end of study
- Secondary Outcome Measures
Name Time Method OS median 5 years OS defined as the time from randomization to all-cause death through the end of study
Percentage of patients with adverse events 2-3 years To assess the toxicity of adjuvant chemotherapy by CTCAE v5.0
Changes in patient-reported quality of life 2-3 years To assess the mean changes from baseline score in patient-reported quality of life using EORTC QLQ-C30
Trial Locations
- Locations (1)
Cancer Hospital & Institute Chinese Academy of Medical Sciences (CAMS)
🇨🇳Beijing, Beijing, China